Medrx Co

Medrx Co Inventory

The Inventory of Medrx Co (4586.T) as of Nov 14, 2026 is 16.93 M JPY. In the previous year, Inventory was 10.02 M JPY — a change of 68.97% (higher).

Inventory

16.93 MJPY

YoY

68.97%

Last updated:

Inventory of Medrx Co is 2025 16.93 M JPY. Inventory of Medrx Co was 2024 10.02 M JPY. It decreases by 68.97% higher compared to the previous year.

The Medrx Co Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
42.44 M JPY
Jan 1, 2019
18.88 M JPY
Jan 1, 2020
19.91 M JPY
Jan 1, 2021
11.79 M JPY
Jan 1, 2022
8.34 M JPY
Jan 1, 2023
10.00 M JPY
Jan 1, 2024
10.02 M JPY
Jan 1, 2025
16.93 M JPY
The Medrx Co Inventory history
YEARInventoryYoY
16.93 MJPY+68.97%
10.02 MJPY+0.18%
10.00 MJPY+19.86%
8.34 MJPY-29.25%
11.79 MJPY-40.79%
19.91 MJPY+5.46%
18.88 MJPY-55.50%
42.44 MJPY-31.10%
61.59 MJPY+46.86%
41.94 MJPY+56.08%
26.87 MJPY+35.68%
19.81 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Inventory of Medrx Co is 16.93 M JPY in 2025.

Inventory of Medrx Co changed from 10.02 M JPY to 16.93 M JPY, representing a 68.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory Medrx Co since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Medrx Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Medrx Co

All Key Metrics — Medrx Co